Baird Medical Investment Holdings

BDMD · NASDAQ

$0.4455−$0.0075 (−1.66%)TodayMarket closed ·
Prev close $0.453

Latest news

  • News

    Baird Medical Announces Additional Medical Device Registrations In Vietnam And Preliminary Regulatory Approval In Egypt

  • Press releaseGlobe Newswire

    Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

  • Press releaseGlobe Newswire

    Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

  • Press releaseGlobe Newswire

    Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

  • Press releaseGlobe Newswire

    Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

  • News

    Baird Medical Says BD-GT Microwave Ablation System And T-1610 Disposable Microwave Ablation Needle Receive Product Registrations From Drug Regulatory Authority Of Pakistan

  • Press releaseGlobe Newswire

    Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

  • News

    Baird Medical And Tianjin Yuanshan Sign Strategic Cooperation Agreement To Establish Long-Term Partnership Focused On Global Development And Commercialization Of Next-Gen IRE Technologies

  • Press releaseGlobe Newswire

    Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

  • Press releasePRNewswire

    Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina

  • Press releasePRNewswire

    Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion

  • News

    Baird Medical Investment FY EPS $(0.98) Down From $0.57 YoY, Sales $22.537M Down From $37.037M YoY

  • Press releasePRNewswire

    Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releasePRNewswire

    Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia

  • Press releasePRNewswire

    Baird Medical Expands Global Reach with Regulatory Clearance in Argentina

  • Press releasePRNewswire

    Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Baird Medical Accelerates Global Registration of AI-Driven Surgical Software

  • Press releasePRNewswire

    Baird Medical Accelerates U.S. Expansion at NASOIE 2026

  • Press releasePRNewswire

    Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology

  • Press releasePRNewswire

    Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences

  • Press releasePRNewswire

    Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital

  • Press releasePRNewswire

    Baird Medical Accelerates Global Commercial Roadmap with Strategic Clinical Education Initiatives in the U.S. and Japan

  • Press releasePRNewswire

    Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass

  • Press releasePRNewswire

    Baird Medical Accelerates Global Commercial Roadmap through Strategic Partnership with Stonewood Key Capital

  • Press releasePRNewswire

    Baird Medical Highlights Strategic Engagement at 2026 J.P. Morgan Healthcare Conference

  • Press releasePRNewswire

    Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam

  • Press releasePRNewswire

    Baird Medical Establishes U.S. Manufacturing Base to Accelerate Global Expansion and Future R&D

  • Press releasePRNewswire

    Baird-Sponsored Microwave Ablation Training Enhances Thyroid Treatment Capabilities for Leading Arizona Surgeon

  • Press releasePRNewswire

    Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion

  • Press releasePRNewswire

    Baird Medical Enters Egyptian Market with First Successful Bone Tumor Ablation

  • Press releasePRNewswire

    Baird Medical's MWA System Achieves Successful Medicare Reimbursement at Prominent New York Practice

  • Press releasePRNewswire

    Baird Medical Announces First Successful Liver Tumor Ablation in Bangladesh

  • Press releasePRNewswire

    /C O R R E C T I O N -- BDMD/

  • Press releasePRNewswire

    Baird Medical Fosters Advanced Physician Training at International Thyroid Microwave Ablation Workshop in Malaysia

  • Press releasePRNewswire

    Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

  • NewsAvi Kapoor

    Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • NewsAvi Kapoor

    New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • NewsAvi Kapoor

    Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Dow Surges Over 300 Points; US Initial Jobless Claims Decline

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.